Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Osteo Arthritis Knee
Interventions: Active comparator: chloroprocaine, Sham comparator: saline; Procedure
Lead sponsor: Duke University; Other
Eligibility: 56 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Hypoxemic Respiratory Failure
Interventions: L-Citrulline, Placebo; Drug
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Cystitis, Interstitial
Interventions: Certolizumab pegol, Placebo; Biological · Drug
Lead sponsor: ICStudy, LLC; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Escondido, California

Conditions: Atherosclerosis
Interventions: Polyarginine, Vein soak treated with Lactated Ringers Solution; Drug
Lead sponsor: St. Luke's Hospital, Chesterfield, Missouri; Other
Eligibility: 25 Years to 95 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Conditions: Pain
Interventions: Dexmedetomidine, Normal Saline; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Anemia, Sickle Cell, Pain
Interventions: Fentanyl Citrate, Normal Saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Post-operative Pain, Respiratory Depression
Interventions: Dexmedetomidine, Placebo (Normal Saline); Drug · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Fasciitis, Plantar
Interventions: AmnioFix® Injectable, Saline Injection; Other · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Tucson, Arizona • Fresno, California • San Francisco, California + 7 more

Conditions: Type 2 Diabetes Mellitus, Healthy
Interventions: GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Morbid Obesity
Interventions: IV acetaminophen, IV normal saline; Drug
Lead sponsor: McLaren Regional Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Infections, Meningococcal
Interventions: rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 3,657 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 64
States / cities: Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more

Conditions: Asthma, Allergies
Interventions: Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage, Phlebotomy; Biological · Procedure
Lead sponsor: Andrew D. Luster, M.D.,Ph.D.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, Placebo, FX006 16 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 36 more

Conditions: Ventral Hernia Repair
Interventions: Gemcitabine/ clindamycin, Normal saline; Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Malaria
Interventions: PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline; Biological · Other
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hemorrhage
Interventions: Oxytocin + normal saline, Normal saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Congenital Heart Disease
Interventions: Antithrombin III, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 1 Day to 180 Days
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Kidney Injury
Interventions: erythropoietin, saline; Drug
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Opioid Dependence, Pain, Addiction
Interventions: Placebo, Hydromorphone, Buprenorphine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post Surgical Pain
Interventions: Bupivacaine 0.25%, Dexamethasone, normal saline; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Transesophageal Echocardiography Contrast Agents
Interventions: normal saline, human albumin, human albumin and propofol; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Infra-orbital Hollows, Skin Quality Improvement
Interventions: RhPDGF-BB, Normal Saline; Biological · Drug
Lead sponsor: Lynch Regenerative Medicine; Network
Eligibility: 21 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Newport Beach, California • Santa Monica, California • Chicago, Illinois + 3 more

Conditions: Influenza Type A, Influenza Type B, Influenza
Interventions: SAB-176, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Analgesic Value of Adductor Canal vs Femoral Block After Total Knee Arthroplasty

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Evaluation of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Patients

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial)

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%

Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations

Phase 2 Evaluation of Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) Injection for the Treatment of Infraorbital Hollowing

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants